About: Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $31.68 (+1.80%)
PHVS NASDAQ Pharvaris BV
Pharvaris BV share price
PHVS price activity
Last Price
$31.680
Change (24hr)
0.56 USD (1.80%)
Volume
320.32K
Volume (4w avg)
-
Open
$30.97
Day Range
$30.58 - $32.08
Previous Close
$31.12
Last Trade
07 Oct, 8:00 pm GMT+0
Delayed
07 Oct, 8:00 pm GMT+0
PHVS price performance
Delayed
07 Oct, 8:00 pm GMT+0
PHVS Market Signals